4 results about "Mirabegron" patented technology

The present invention relates to extended release composition of Mirabegron and process of manufacture thereof. The extended release composition of mirabegron comprising non-polymeric hydrophobic excipient as release controlling agent along with one or more pharmaceutically acceptable excipient is used in the treatment of symptoms associated with overactive bladder.

One embodiment of the present invention provides a mirabegron-containing preparation that suppresses formation of N-nitroso mirabegron. A mirabegron-containing preparation according to one embodiment of the present invention includes a mirabegron-containing tablet, blister packaging that accommodates and encloses the mirabegron-containing tablet, pillow packaging that encloses the blister packaging that accommodates the mirabegron-containing tablet, and a zeolite that is provided in the space between the blister packaging and the pillow packaging. The N-nitroso mirabegron content of the mirabegron-containing tablet after storage for 3 months at 40°C and a relative humidity of 75% may be 50% or less of an acceptable limit value for N-nitroso mirabegron.

The invention discloses a mirabegron sustained release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The mirabegron sustained-release tablet comprises the following components in parts by mass: 60-90 parts of a mirabegron sustained-release compound, 20-80 parts of a film-forming agent, 1-20 parts of a plasticizer, 0-3 parts of a thickening agent and 0-1 part of a sweetening agent. The mirabegron sustained-release preparation prepared by the invention not only realizes the sustained-release effect of mirabegron, but also realizes accurate and controllable dosage, can be rapidly disintegrated in the oral cavity without water, is extremely convenient in administration mode, and greatly improves the medication compliance of patients.

The present invention relates to bilayer tablet pharmaceutical compositions comprising an immediate-release layer comprising solifenacin succinate as active ingredient, a binder, a distintegrant and at least one pharmaceutically acceptable excipient, a prolonged-release layer comprising mirabegron as active substance and at least one pharmaceutically acceptable excipient.